This site is intended for health professionals only

Sunday 21 July 2019
LatestNews
Share |

Latest News

Ivacaftor may reduce common infections in patients with CF

Friday 19th July 2019
Patients with cystic fibrosis who take ivacaftor appear to have fewer respiratory infections over time than those not taking the drug, according to research published online in the Annals of the American Thoracic Society.
 
Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Ivacaftor (Kalydeco®) is prescribed to patients whose CF is caused by a "gating...